Latest Articles
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer FiercePharma
Published: May 9, 2024, 7 a.m.
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint Healio
Published: May 9, 2024, 7 a.m.
Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop - BioSpace
Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop BioSpace
Published: May 9, 2024, 7 a.m.
Merck's endometrial cancer therapy fails trial - ETHealthWorld
Merck's endometrial cancer therapy fails trial ETHealthWorld
Published: May 9, 2024, 7 a.m.
Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia - Nature.com
Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia Nature.com
Published: May 4, 2024, 7 a.m.
After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar - Health Matters
After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar Health Matters
Published: May 3, 2024, 7 a.m.
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials - The Lancet
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials The Lancet
Published: April 30, 2024, 7 a.m.
Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer - The Lancet
Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer The Lancet
Published: April 30, 2024, 7 a.m.
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate - Frontiers
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate Frontiers
Published: April 29, 2024, 7 a.m.
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer - OncLive
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer OncLive
Published: April 24, 2024, 7 a.m.
Link copied to clipboard!